drugset / Trial / NCT02030483
Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma
Phase 1
Terminated
9 enrolled
Weill Medical College of Cornell University
Celgene Corporation · collabPfizer · collab
NaSingle-groupOpen-labelTreatment
Summary
Our hypothesis is that treating relapsed or refractory multiple myeloma with PD 0332991 (Palbociclib) in combination with lenalidomide will result will be both effectively inducing myeloma plasma cell death as well maintaining a favorable side effect profile.
Timeline
- Start
- 2014-02
- Primary completion
- 2016-07
- Completion
- 2016-07
Outcome
Outcome not reported
Stopped (Enrollment): “The company providing one of the study drugs withdrew its support due to low enrollment. Therefore, we had to close the study due to lack of funding.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 20 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 5 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 10 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 15 mg | Oral |
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |
| Subject | Palbociclib | Small molecule | 75 mg | Oral |
| Subject | Palbociclib | Small molecule | 100 mg | Oral |
| Subject | Palbociclib | Small molecule | 125 mg | Oral |
| Subject | Palbociclib | Small molecule | 150 mg | Oral |